just listened to the recording...three pages of scribbled
just listened to the recording...three pages of scribbled notes!
Some thoughts
- They are prioritizing two of the newly acquired ANDA's. Specifically going after small markets with only one generic competitor. The Loxapine is a very small market, about $20,000,000. The three listed manufacturers are Activas, Watson and Mylan. Now Actavis and Watson are one and the same and of course the had to divest Loxapine. So it's now Elite and Mylan splitting a $20,000,000 market. So this could easily become a $4,000,000 drug. The other one if I had to guess is Dantrolene Sodium. The four listed manufacturers are: Actavis, Impax, JHP and US WorldMeds. But I'm not really sure on this one. The "big fish/small pond" strategy is perfect.
- I'd like to be Nasrat's real estate agent...
- Clinical trials start in November, Nasrats estimation. So results could come in what 3-4 months after?
- The shift to ART development being the biggest company priority is significant. JT righted the ship, got financing, got cashflow from generics and now we are ready for the next leg up.
- MIK001 deal remains with Mikah, which continues to exist.
- We have full title now to Phendimetrazine so will accelerate profitability and sales here.
- Mikah previously only marketed Phendimetrazine to clinics, now Elite can expand that market
- They have already met with potential marketing partner for this basket of drugs.
- They are resource limited so again watch for aggressive push on two of the new ANDA's with the rest back burnered for a bit.
- I was impressed by the number of callers given the short notice on the call.
- Nasrats desire/plan is to be back on NASDAQ in 2 years.
- We have another CC next week. Positive earnings and maybe naltrexone launch?
Elite Pharmaceuticals Inc (ELTP) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...
Continue Reading
Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...
Continue Reading
Sydney just became the map pin for a fairly serious travel-content land grab. Trip.Best, Trip.com Group's ranking brand, has rolled out its 2027 Annual Rankings with coverage of all seven continents for the first time. This is not an earnings release, and nobody should pretend a hotel list magically turns into revenue by lunchtime. Still, the jump from 85 to 98 annual...
Continue Reading
November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...
Continue Reading
A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...
Continue Reading
A $23.50 cash offer can look wonderfully tidy until somebody asks how the number was built. That is where Surgery Partners shareholders find themselves after Halper Sadeh LLC said it is investigating the proposed sale of Surgery Partners, Inc. to HealthSpan Partners. The firm is examining whether the company’s board obtained a fair price, ran a conflict-free process,...
Continue Reading
Holiday charity works best when it gives people something tangible to gather around, and Franklin County has found a pretty sturdy version of that formula. Its eighth annual Festival of Trees opens at 4 p.m. Saturday, November 21, at the Franklin County 11/30 Visitors Center in downtown Chambersburg, carrying the theme A Salute To Veterans. More than 80 decorated trees...
Continue Reading
Anthropic shares have landed on Bybit Stocks, and the headline is simple enough: eligible customers can trade ANT after the company’s public listing. But this is one of those announcements where the plumbing deserves as much attention as the shiny new ticker. A platform can make access feel effortless right up until a jurisdiction rule, a verification hurdle, or a...
Continue Reading
Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...
Continue Reading
Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...
Continue Reading
Top 5 Most Recently Viewed Articles
Barclays Reconfirms Target for Deere & Co Barclays recently reaffirmed its Overweight rating on Deere & Co (NYSE: DE) and maintained a $400 price target, amidst an ongoing dialogue surrounding the right to repair. This discussion has re-emerged in the spotlight, temporarily impacting Deere's share price before it regained ground. The analyst noted that this issue has been...
Continue Reading
A Fresh Take on Infection Control Some days you stumble across an idea that just clicks—like the latest gadget for hospitals. Forget complex systems or high-tech cameras; this is about a simple sign that screams 'stop!' before you walk into trouble. It’s designed to safeguard hospital staff by alerting them to take precautions before entering rooms with infectious...
Continue Reading
JPMorgan Adjusts NOV Stock Outlook Recently, JPMorgan made changes to its financial outlook for NOV Inc. (NYSE: NOV), a key player in the energy equipment and services sector. The investment firm lowered its price target from $23 to $22 but maintained an Overweight rating on the stock. This adjustment was driven by expectations of a slowdown in North American operations...
Continue Reading
Madrigal Pharmaceuticals Strengthens Workforce with New Grants Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a leading biopharmaceutical company dedicated to innovative treatments for metabolic dysfunction-associated steatohepatitis (MASH), has recently taken a significant step to bolster its team. The company announced granting equity inducement awards to 76 new...
Continue Reading
Pomerantz Law Firm's Investigation into Abacus Global Management In recent news, the Pomerantz Law Firm has embarked on an investigation regarding Abacus Global Management, Inc. (NASDAQ: ABL). This investigation revolves around potential securities fraud and other unlawful business practices committed by the company and some of its executive members. For investors...
Continue Reading